Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Huntington Disease: early-phase trial registry
18 of 36 indexed Huntington Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #419 of 28,707 conditions by registered trial count.
36 US clinical trials · 18 currently recruiting · #419 of 28,707 conditions by registered trial count
Huntington Disease: 36 US clinical trials tracked, 18 recruiting.
Huntington Disease is the subject of 36 registered US clinical trials on ClinicalTrials.gov, 18 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Hoffmann-La Roche, running 3 of these trials.
Enrollment posture brief
Registry condition huntington-disease
OPEN 18 | RECR 50% | LATE 3 | EARLY 9 | RANK #419 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Huntington Disease lists 18 open slots (50% of 36 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Huntington Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Huntington Disease is recruiting above its size-band peers.
18 of 36 indexed trials (50%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Huntington Disease trials is spread across many organizations.
Hoffmann-La Roche accounts for 3 of 36 trials (8.3%). 29 distinct sponsors appear on at least one study for this condition label.
-
Typical Huntington Disease enrolment sits around 109 participants.
Median target enrolment is 109 among the 36 trials that report a genuine target (sentinel values excluded). 16 of those (44.4%) plan for fewer than 100 participants.
-
Huntington Disease splits between interventional and observational designs.
19 interventional and 17 observational studies make up this index (52.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
36 total, page 1 of 1
NYSCF Scientific Discovery Biobank
New York Stem Cell Foundation Research Institute
NCT06203106
Retinal Imaging in Neurodegenerative Disease
Duke University
NCT03233646
Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers
University of Washington
NCT05596760
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
xCures
NCT06539169
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals
NCT07326709
Longitudinal Endpoint Assessment of Disease Burden in HD
Huntington Study Group
NCT06475898
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
Hoffmann-La Roche
NCT06667414
Huntington's Disease Biobank: Advancing Remote Monitoring and Deep Phenotyping
Stanford University
NCT06941662
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
University of Virginia
NCT07213648
Gait Analysis in Neurological Disease
Beth Israel Deaconess Medical Center
NCT02994719
Extracellular Vesicles for HD
University of Central Florida
NCT06082713
Digital Measures for Clinical Trial Endpoints in Huntington's Disease
University of Rochester
NCT07010705
Cognitive Assessment Tools for Huntington's Disease.
Ohio State University
NCT06546488
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
Hoffmann-La Roche
NCT06826612
Gut Microbiomes in HD
University of Central Florida
NCT06448546
Home-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease
The University of Texas Health Science Center at San Antonio
NCT06843252
Home-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease
The University of Texas Health Science Center, Houston
NCT05326451
Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study
Sanguine Biosciences
NCT05773196
Neurobiological Predictors of Huntington's Disease (PREDICT-HD)
Jordan Schultz
NCT00051324
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
Hoffmann-La Roche
NCT05686551
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
Vanderbilt University Medical Center
NCT04713982
Prospective Huntington At Risk Observational Study
Huntington Study Group
NCT00052143
A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease
Medivation
NCT00920946
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
Amarin Neuroscience
NCT00146211
Preparing for Prevention of Huntington's Disease (PREVENT-HD)
University of Wisconsin, Madison
NCT04818060
A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
Teva Branded Pharmaceutical Products R&D
NCT00724048
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
Prana Biotechnology Limited
NCT01590888
Genetic Risk: Whether, When, and How to Tell Adolescents
Johns Hopkins University
NCT03421327
Creatine Safety and Tolerability in Premanifest HD: PRECREST
Massachusetts General Hospital
NCT00592995
Mitochondrial Biomarkers in Huntington's Disease
University Hospitals Cleveland Medical Center
NCT04515550
Time-Restricted Eating in Huntington's Disease: A Clinical Pilot Study
Oregon Health and Science University
NCT06490367
Move to Improve: Telehealth Exercise to Music for HD
Ohio State University
NCT05270681
Atomoxetine and Huntington's Disease
University of Iowa
NCT00368849
A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)
Pfizer
NCT00988624
Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study
The University of Texas Health Science Center, Houston
NCT04421339
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan
Pfizer
NCT00788047
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Huntington Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Huntington Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Huntington Disease page
36 registered trials, 18 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 18 Huntington Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Hoffmann-La Roche sponsors the most Huntington Disease trials on record, review their full trial history before evaluating a specific study. See Hoffmann-La Roche's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Huntington Disease condition card totals 36 registered trials; most-linked intervention Placebo; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.